ArticleGene therapy2006
Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.
Article in Gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 99 citations in OpenAlex.
- Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy?Genes & diseases · 2023Review
- Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications.Frontiers in cell and developmental biology · 2021Review
- Intratumoral expression using a NFkB-based promoter enhances IL12 antitumor efficacy.Cancer gene therapy · 2019Article
- Osmolytes in vaccine production, flocculation and storage: a critical review.Human vaccines & immunotherapeutics · 2019Review
- Alarmin augments the antitumor immunity of lentiviral vaccine in ectopic, orthotopic and autochthonous hepatocellular carcinoma mice.Theranostics · 2019Article
- The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.Expert review of vaccines · 2018Review
- The Journey ofFrontiers in immunology · 2018Review
- Article
- Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Dendritic cell-based immunotherapy.Cell research · 2017Review
- Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian carcinoma.Oncology letters · 2016Article
- LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.Molecular therapy oncolytics · 2016Article
- Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.Journal of immunology research · 2015Review
- In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice.Biomacromolecules · 2014Article
- Immunogenicity of targeted lentivectors.Oncotarget · 2014Article
- Article
- Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Diminished Memory T-Cell Expansion Due to Delayed Kinetics of Antigen Expression by Lentivectors.PloS one · 2013Article
- Article
- Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells.Gene therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ex vivo lentivirally transduced dendritic cells (DC) have been described to induce CD8+ and CD4+ T-cell responses against various tumor-associated antigens (TAAs) in vitro and in vivo. We report here that direct administration of ovalbumin (OVA) encoding lentiviral vectors caused in vivo transduction of cells that were found in draining lymph nodes (LNs) and induced potent anti-OVA cytotoxic T cells similar to those elicited by ex vivo transduced DC. The cytotoxic T-lymphocyte (CTL) response following direct injection of lentiviral vectors was highly effective in eliminating target cells in vivo up to 30 days after immunization and was efficiently recalled after a boost immunization. Injection of lentiviral vectors furthermore activated OVA-specific CD4+ T cells and this CD4 help was shown to be necessary for an adequate primary and memory CTL response. When tested in therapeutic tumor experiments with OVA+ melanoma cells, direct administration of lentiviral vectors slowed down tumor growth to a comparable extent with the highest dose of ex vivo transduced DC. Taken together, these data indicate that direct in vivo administration of lentiviral vectors encoding TAAs has strong potential for anticancer vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.